Janssen-Cilag Polskasp. z o.o.

Advertising agencies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-12-17
Share capital
25 050 000,00 PLN
Activity description

Janssen-Cilag Polska is a pharmaceutical company that focuses on innovative medicine, particularly in oncology, immunology, and neuroscience. It has developed and received FDA approval for several treatments, including RYBREVANT FASPRO™ for EGFR-mutated non-small cell lung cancer, CAPLYTA® for major depressive disorder, and DARZALEX FASPRO® for high-risk smoldering multiple myeloma. The company also acquired Halda Therapeutics to enhance cancer treatment options.

Registered address
Iłżecka 24, 02-135 Warszawa, Poland
Website
janssen.plWebsite active
Social media
Electronic delivery address
AE:PL-98422-76133-RIAIU-27

Financials

Revenue history (in m)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 323.93mMedianUSD 110.96kAverageUSD 1.12m
Net profit
This companyUSD 15.77mMedianUSD 3.71kAverageUSD 81.30k
Operating costs
This companyUSD 303.89mMedianUSD 97.57kAverageUSD 1.01m
Assets
This companyUSD 153.83mMedianUSD 57.63kAverageUSD 683.12k

Industry

Bank accounts

Registered as a VAT taxpayer on 2003-10-31. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Buildings and premises
PLN 37,728

MSiG notices

Publication dateEvent
Feb 6, 2019Merger plan

Public aid

No public aid cases recorded in the last 10 years.

Tenders

983 tenders recorded as contractor: 164 national ($10,813,301) and 819 EU ($8,011,946,853).

SubjectAmount
31/26 – Dostawa produktów leczniczych
–
Dostawa produktów leczniczych oraz leków w ramach programów lekowych
–
Zakup i sukcesywna dostawa produktów leczniczych stosowanych w programach lekowych i RDTL(5]
–

Public sector contracts

Janssen-Cilag Polska is the contractor in 213 public sector contracts, worth PLN 275.27m in total. They were signed with 73 public buyers. The largest number (2) were signed with Uniwersyteckie Centrum Kliniczne.

Public buyerValue
Wojewódzki Szpital Zespolony w ElbląguPLN 2,437,507
Szpital Uniwersytecki Nr 2 Im. Dr Jana Biziela w BydgoszczyPLN 6,607,428
Szpital Chorób Płuc Im. Św. Józefa w PilchowicachPLN 42,360
Górnośląskie Centrum Medyczne Im. Prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w KatowicachPLN 21,556
Szpital Specjalistyczny Im. Henryka Klimontowicza w GorlicachPLN 56,435

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Authorized Representatives

Radu Birsan Hirtie – Attorney-in-fact (joint)
Julie Enevold Brooker – Management Board Member
Przemysław Brzeski – Management Board Member
Iwona Gąsiorowska – Attorney-in-fact (joint)
Marcin Soliwodzki – Attorney-in-fact (joint)

Manner of representation

In the case of a management board consisting of one or two members, the members of the management board represent the company individually before public authorities and third parties, in court and out of court. In the case where the company's management board consists of three or more members, the company is represented by two members of the management board acting jointly, or by a member of the management board acting jointly with an independent commercial proxy or any of the joint commercial proxies.

Ownership

OwnerShare valueStake
Johnson & Johnson International Financial Services Company
$6,766,612.64100%

Beneficial owners

Person

Competitors

Name
RTB HouseS.A.
RE58S.A.
OEX CursorS.A.
AMSS.A.
Świat ZdrowiaS.A.
MediaexpertS.A.

Change history

DateEvent
2017-01-27PKD change
2015-03-17PKD change
2007-08-21Address change
2003-01-16Share capital change
2003-01-16Name change

FAQ

Last updated: 2026-10-03